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Cannabidiol and cannabigerol are two active pharmaceutical ingredients, derived 25	
from cannabis plant. In the present study, CBD and CBG were co-formulated with 26	
polyvinyl(pyrrolidone) (PVP) and Eudragit L-100, using electrohydrodynamic 27	
atomization (electrospinning). The produced fibers were smooth and uniform in 28	
shape, with average fiber diameters in the range of 700 -900 nm for PVP fibers 29	
and 1- 5 µm for Eudragit L-100 fibers. Drug loading and encapsulation efficiency 30	
were calculated for all formulations, with high encapsulation efficiencies (over 31	
90%). Both in vitro release and in vitro disintegration tests of the formulations in 32	
SCF and SGF indicated the rapid dissolution of the fibers and the subsequent 33	
rapid release of the drugs. The study concluded that the electrospinning process is 34	
a fast and efficient method to produce drug-loaded fibers with enhanced 35	
properties, suitable for the per os administration of cannabinoids.  36	
 37	













Cannabis and plant-derived cannabinoids have received increasing attention for their 49	
potential use for medicinal purposes (1). More than one hundred phytocannabinoids 50	
have already been isolated and identified from Cannabis sativa (2). Phytocannabinoids 51	
are known to interact with the human body via the endocannabinoid system, by binding 52	
with CB1 or CB2 receptors, resulting in either an agonistic or antagonistic downstream 53	
effect (3,4). Due to the wide distribution of these receptors, cannabinoids contribute 54	
significantly to human body processes (5,6). One of the most important and most 55	
extensively studied cannabinoids, is Δ9-tetrahydrocannabinol (Δ9-THC), mainly due 56	
to its psychoactive properties. However, non-psychoactive phytocannabinoids, such as 57	
cannabidiol (CBD) and (CBG) have received the attention of the scientific community, 58	
as they exhibit similar properties with Δ9-THC. CBD is the most promising of the non-59	
psychoactive cannabinoids due to its pharmacological actions and its abundance in 60	
hemp plants (7,8). CBD has been studied for its potential anti-inflammatory activity, 61	
antitumoural and anti- angiogenic properties, anti-nausea action, and its ability to 62	
alleviate anxiety and pain (9–13). In addition to these, CBD has been asserted of playing 63	
a major role in the treatment of various medical conditions, such as multiple sclerosis, 64	
Parkinson’s disease,  Alzheimer's disease, epilepsy, rheumatoid arthritis, and diabetic 65	
complications (14–19). Food and Drug Agency (FDA) has already approved the use of 66	
CBD for the treatment of seizures associated with Lennox-Gastaut (LGS) or Dravet 67	
syndrome (DS) in pediatric patients, and marketed products based on highly purified 68	
CBD (Epidiolex®) are already being administered for the treatment of these diseases. 69	
Another interesting phytochemical extracted from Cannabis sativa, CBG, plays 70	
one of the most significant roles in the biochemistry of the cannabis plant, as it is a 71	
chemical precursor to other cannabinoids.  Recently, a growing amount of research in 72	
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CBG’s mechanism of action has revealed its polypharmacological profile, proving its 73	
potential health benefits (20). It is suggested that CBG interacts with the two G-protein-74	
coupled receptors, CB1 and CB2, and it is claimed to increase the level of anandamide 75	
(the natural ligand of the endocannabinoid receptors), increasing in this way the levels 76	
of dopamine, and thus regulating functions such as sleep, mood, and appetite (21). One 77	
of the most promising beneficial effects of CBG use is its potential anti-inflammatory, 78	
antibacterial, and antidepressant properties (22,23). Additionally, CBG is studied for 79	
glaucoma treatment as it contributes to the regulation and lowering of the intraocular 80	
pressure (20). Finally, CBG has a positive effect on inhibiting tumor growth in animal 81	
models of colorectal cancer (24).  82	
Owing to their low oral bioavailability, efforts have been made towards the 83	
development of novel delivery systems via different routes of administration, such as 84	
transdermal, intranasal, and transmucosal (25,26). Nevertheless, the oral route is the 85	
most common due to ease of administration. To this context, a wide range of 86	
formulations aimed for oral delivery has been reported including lipid-based delivery 87	
systems (SNEDDS), gastro retentive dosage forms, amorphous solid dispersions, and 88	
cyclodextrin inclusion complexes (27–31), focusing mainly to cannabinoids solubility 89	
enhancement effect. 90	
In this direction, the concept of the development of solid dosage forms to deliver 91	
cannabinoids is a persistent challenge. The electrospinning process is considered as one 92	
of the most promising drug delivery platforms, aiming to overcome issues related to 93	
low dissolution rate (32). Electrospun-based drug delivery systems have flourished in 94	
several therapeutic fields due to their unique characteristics, such as flexible pore sizes, 95	
high surface area to volume ratio, and ease of production, resulting in ameliorating drug 96	
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dissolution and subsequently to enhanced bioavailability of poorly water-soluble active 97	
pharmaceutical ingredients (APIs) (32). 98	
The present study is focused on developing, for the first time, electrospun fibers 99	
loaded with CBD or CBG (used as model cannabinoids). Two different forms of 100	
electrospun fibers based on a nonionic hydrophilic polymer PVP and a pH-responsive 101	
polymer (Eudragit-L100), loaded with CBG or CBD, were developed. PVP and 102	
Eudragit-L100 were selected as model excipients (matrix-carriers), due to their ability 103	
to improve the dissolution profiles when co-formulated with poorly water-soluble APIs, 104	
by forming amorphous solid dispersions (ASDs) (33,34). The electrospinning process 105	
is one of the most efficient routes for the direct production of ASDs (32,35,36), thus it 106	
was selected in this study for the co-formulation of model cannabinoids with two model 107	
excipients, towards the improvement of the solubility profiles of both CBD and CBG.  108	
 109	
Materials and Methods 110	
Materials 111	
All reagents used were of standard analytical grade. CBD (crystals, > 99% CBD, 1% 112	
terpenes by GC-MS, Enecta, Italy; provided by Hempoil®, Athens, Greece) and CBG 113	
(crystals, > 99% CBD, 1% terpenes by GC-MS, Enecta, Italy; provided by Hempoil®, 114	
Athens, Greece) were used as received with no further purification. All cannabinoids 115	
were stored in amber vials purged with nitrogen to ensure an inert atmosphere. PVP 116	
(Povidone, average Mw=1,300,000 by LS, Sigma-Aldrich, Darmstadt, Germany) and 117	
Eudragit L-100 (Poly(methacrylic acid-co-methyl methacrylate) 1:1, Rohm America, 118	
Darmstadt, Germany) were stored in a desiccator at room temperature to avoid any 119	
interaction with ambient humidity. All other materials and reagents were of analytical 120	
or pharmaceutical grade and were used as received.    121	
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Electrospinning Solution Preparation 122	
The electrospinning solutions were prepared according to literature (35,37), with a 123	
slight modification. In a typical experiment, 10% w/v and 20% w/v electrospinning 124	
solutions were prepared by dissolving the respective polymer (PVP or Eudragit L-100) 125	
in ethanol, at room temperature, under magnetic stirring. A predetermined amount of 126	
the cannabinoids was added to the polymer solutions and the system was kept under 127	
magnetic stirring for at least 30 min before any further processing, to ensure complete 128	
dissolution. The different solution compositions are summarized in Table 1. 129	
 130	
Dynamic Viscosity Measurements 131	
The dynamic viscosity (µ) of the prepared solutions was measured based on previously 132	
reported studies (36). The dynamic viscosity of solutions of 10% w/v PVP and 20% 133	
w/v Eudragit L-100 in ethanol was measured using a rotational viscometer (Alpha 134	
series, Fungilab, Barcelona, Spain) at 25 °C.  135	
 136	
Conductivity Measurements 137	
The electrical conductivity of the polymer solutions was evaluated using a conductivity 138	
meter (Fisherbrand™ accumet™ Basic AB30 Conductivity Meter, Fisher Scientific, 139	
Loughborough, UK). Briefly, 5mL of each sample was incorporated in a glass tube and 140	
the measurement was started by immersing the electrode in the solution. The 141	
conductivity value was calculated by the average value of three independent 142	
measurements for each sample at ambient temperature. 143	
 144	
Electrospinning Process 145	
Electrospun fibers were prepared using an Electrospinning System (Starter Kit, E-Fiber 146	
electrospinning system, SKE Research Equipment®, Bollate, Italy). The polymer/drug 147	
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solutions were transferred in a 2 mL syringe, and the entrapped air was removed. The 148	
syringe was fitted with an 18-gauge needle and mounted onto the syringe pump 149	
apparatus. The feed rate was set to 1.0 mL/h and 0.5mL/h for PVP and Eudragit-L100 150	
solutions, respectively. The applied voltage was constant at 15 ± 2 kV. The distance 151	
between the needle tip and the collector was set to 15 cm. All process parameters were 152	
selected according to literature (35–38) and to a series of trial experiments. The process 153	
was carried out under ambient conditions. The fabricated fiber mats were collected and 154	
stored at a desiccator in dark, at room temperature. 155	
 156	
Scanning Electron Microscopy (SEM) 157	
The morphology of the electrospun samples was studied by a scanning electron 158	
microscope (Phenom ProX, ThermoFisher Scientific, Massachusetts, USA) in a high 159	
vacuum. Conductive double-sided carbon adhesive tape (TED Pella, Redding, 160	
California, USA) was used to mount the samples, which were subsequently coated by 161	
gold, using an ion sputtering device (Quorum SC7620, East Sussex, UK). A 15 kV 162	
accelerating voltage was applied during the measurements. For fiber diameters 163	
distribution calculation, at least 100 measurements per sample were evaluated using the 164	
Phenom FiberMetric - Fiber Analysis Software.  165	
 166	
High-Performance Liquid Chromatography (HPLC) 167	
The quantification of CBD and CBG was performed by high-performance liquid 168	
chromatography (HPLC). The system consisted of a pump (LC-10 AD VP), an auto-169	
sampler (SIL-20A HT), and an ultraviolet-visible detector (SPD-10A VP, Shimadzu, 170	
Kyoto, Japan). The chromatographic conditions were adapted from the literature, with 171	
modifications (30,39). The stationary phase for CBD was a Discovery HS C18 (15 cm 172	
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x 4.6 mm, 3 µm) column and the mobile phase consisted of a mixture of (A) acetonitrile 173	
and (B) phosphate buffer (KH2PO4, 0.0126M, pH 5.0), A:B 80:20. The flow rate was 174	
set at 1.0 mL/min and the injection volume was 30 µL. The retention time of CBD and 175	
CBG was 5.5 min and 5.0 min, respectively. Standard samples were tested in the range 176	
of 0.5-100 µg/mL (R2 ≥ 0.9999). Typical chromatograms of CBD and CBG are given 177	
as supplementary data (Figure S1 & S2).  178	
 179	
 Drug Loading 180	
The drug loading and the entrapment efficiency of the samples were measured 181	
according to the literature (38). Briefly, the prepared fibers were accurately weighed 182	
(10 mg) and dissolved in a mixture of acetonitrile:water 80:20 (1 mL). After complete 183	
dissolution, the drug loading and the entrapment efficiency were calculated employing 184	
HPLC analysis. The solution concentration was determined using a preconstructed 185	
calibration curve of the respective API. The results were presented as the average value 186	
of three independent measurements for each sample. CBD and CBG content, along with 187	
encapsulation efficiency was expressed according to the following equations:  188	
Loading Capacity (%)= 100 × Wdrug/Wdrug loaded fiber   (1) 189	
where Wdrug is the weight of the drug in fibrous film and Wdrug loaded fiber is the weight of 190	
fibrous film sample. 191	
Encapsulation Efficiency (%)=100 × Wdrug/Wdrug used in the formulation   (2) 192	
where Wdrug is the weight of the drug in fibrous film and Wdrug used in the formulation is the 193	




Attenuated Total Reflection Fourier Transformed Infrared (ATR-FTIR) 196	
Spectroscopy  197	
The ATR-FTIR spectra were recorded using a Shimadzu IR Prestige-21 spectrometer 198	
(Shimadzu, Kyoto, Japan) with a horizontal Golden-Gate MKII single reflection ATR 199	
system (Specac, Kent, UK) equipped with ZnSe lenses. In this study, each sample was 200	
scanned sixty-four times at 4 cm−1 resolution over the wavenumber range of 750–201	
4000 cm−1. The commercially available software IR Solutions (Shimadzu, Japan) was 202	
used to process the spectral data. 203	
 204	
Thermo-Gravimetric Analysis (TGA) 205	
The thermo-gravimetric analysis was performed by a TGA-50 thermogravimetric 206	
analyzer (Shimadzu, Tokyo, Japan). Briefly, 5mg of the samples were heated at a 207	
heating rate of 10 °C/min from room temperature to 900°C under nitrogen (flow rate of 208	
50mL/min). All experiments were performed in triplicate. 209	
 210	
Differential Scanning Calorimetry (DSC)  211	
DSC analysis was performed by a differential scanning calorimeter 204 F1 Phoenix 212	
DSC apparatus (Netsch GmBH, Selb, Germany). Accurately weighted samples were 213	
sealed in aluminum pans and heated at a rate of 10°C/min, from 20°C to 120°C under 214	
constant nitrogen flow (50 mL/min). The melting point (Tm) of the examined systems 215	
was determined as the peak temperature of the heat flow curve, while enthalpy of fusion 216	
(ΔΗf) was determined as the integrated area in all cases. The standard deviations of 217	
temperatures and enthalpies determined in this work were not higher than 1.0 oC and 218	
3.0 J/g, respectively. The instrument was calibrated for temperature using high purity 219	
benzophenone, indium, and tin, while the enthalpic response was calibrated using 220	
indium. Thermograms were analyzed using the NETZSCH Proteus – Thermal Analysis 221	
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software package version 5.2.1 (NETZSCH, Germany) and all experiments were 222	
conducted in triplicate. 223	
 224	
Powder X-ray Diffractometry (pXRD) 225	
The crystallinity of the samples was evaluated by XRD analysis, performed by an X-226	
ray diffractometer equipped with a LynxEye type detector (D8-Advance, Bruker, 227	
Karlsruhe, Germany). Cu Kα radiation (λ = 0.154059 nm) operated at 40 kV and 40 228	
mA, was used. Data were collected over the 2θ range of 5°-50° at a scanning speed of 229	
0.35 s/step and step size of 0.02°. 230	
 231	
In vitro Release Studies 232	
The release of CBD and CBG was studied in Simulated Gastric Fluid (SGF; NaCl, 2 233	
g/L; 1M HCl, 80mL/L; pH 1.2) and in Simulated Intestinal Fluid (SIF; KH2PO4, 6.805 234	
g/L; NaOH, 0.896 g/L; pH 6.8). Briefly, release studies for PVP fibers were conducted 235	
for 2 h in SGF and SIF, whereas releases studies containing Eudragit L-100 fibers were 236	
monitored over a 4 h period equally divided in SGF and SIF, to mimic the transition 237	
from gastric to intestinal conditions. All samples were fixed in metal-wire frames (30) 238	
to maintain a constant position into the release chamber and they were placed in double-239	
walled glass vessels filled with 40 mL of the release medium, enriched with 0.5% SLS, 240	
to ensure sink conditions (30). The experiments were conducted under constant stirring 241	
(100 rpm), at 37 °C. Aliquots of 1 mL were withdrawn at specific time intervals, 242	
centrifuged at 4500 rcf for 15 min and filtered through 0.45-µm PVDF filters. The 243	
samples were analyzed in triplicate by HPLC to determine the concentration of CBD 244	
and CBG. Kinetic models were fitted to the release data to investigate the possible 245	
release mechanism of the APIs, using DDSolver software (40). The equations 3,4 and 246	
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5 describe the first order model, the Korsmeyer-Peppas model and the Peppas-Sahlin 247	
model, respectively.  248	
dC/dt = K(Cs – C)   (3) 249	
where C is the concentration of the drug, Cs is the equilibrium solubility at the 250	
temperature of the process, K is the first order release constant and t is the time.  251	
Mt/M  = Ktn   (4) 252	
where Mt is the amount of drug released over time t, M  is the amount of drug at the 253	
equilibrium state, K is the constant and n is the exponent of release and it is related to 254	
the release mechanism.  255	
Mt/M  = K1tm + K2t2m    (5) 256	
where K1 and K2 are constants and m is the Fickian diffusion  exponent  for  a  system  257	
of  any  geometrical shape.  258	
 259	
In vitro Disintegration Test 260	
The in vitro disintegration time was determined according to a Petri dish method, with 261	
a slight modification (41,42). A total volume of 2 mL SIF (pH 6.8) or SGF (pH 1.2) 262	
was used for the disintegration test. Briefly, the prepared fibrous mats were placed in a 263	
glass petri dish and covered with the respective disintegration medium. Time-lapse 264	
videos (60 fps) of the procedure were recorded by a digital camera. The test was 265	
completed when the fibrous film was disintegrated. The recorded videos were 266	
converted to frames and the in vitro disintegration time was determined as the time 267	
needed for the complete disintegration of the sample. 268	
 269	
 Water Uptake 270	
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To evaluate the water uptake of Eudragit L-100 fiber mats, precisely weighed samples 271	
were placed in stainless steel mesh and immersed in two different media, SGF (pH 1.2) 272	
and SIF (pH 6.8), respectively. The water uptake of the fibers was monitored for a 273	
period of 2 h. At predetermined times intervals, the samples were removed from the 274	
apparatus, gently blotted with filter paper to remove excess water, and weighed. The 275	
percentage of water uptake was calculated from the following equation: 276	
Water uptake (%) = (W2-W1)/W1×100    (6) 277	
where W2 is the weight of the wetted fibers and W1 is the initial weight of the fibers. 278	
 279	
Statistical Analysis 280	
Data were analyzed using Student’s t-test. The significance level was set at p < 0.05. 281	
 282	
Results 283	
Physical Properties of the Spinning Solutions 284	
Viscosity and conductivity measurements were performed for the spinning solutions 285	
containing PVP and Eudragit L-100 accordingly. The solution containing 10% w/v PVP 286	
had a viscosity of 0.536 ± 0.045 Pa·s, while the viscosity of 20% w/v Eudragit L-100 287	
solution was 0.758 ±0.1 Pa·s (Table 2). The conductivity of PVP and Eudragit L-100 288	
solutions were also measured, and the results are depicted in Table 2.  289	
 290	
Electrospun Fibers Morphology 291	
Figure 1 shows the SEM images of the obtained fibers and the respective histograms of 292	
fibers' diameters distribution for CBD and CBG loaded nanofibers. The morphology 293	
analysis indicates that the applied electrospinning parameters resulted in the production 294	
of smooth and uniform fibers. PVP fibers have been successfully produced in 295	
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cylindrical form while Eudragit L-100 fibers were characterized as flattened (ribbon-296	
like shape). Moreover, the addition of the drugs showed negligible differences with 297	
plain solutions.  298	
 299	
Analysis of CBD and CBG Content  300	
The loading capacity and encapsulation efficiency of all the formulations were 301	
calculated as described above. Table 3 lists the values of all the produced fibers 302	
containing CBD and CBG. The encapsulation efficiency of both drugs is over 90% and 303	
the loading capacity is following the theoretical amount that was initially added in the 304	
solution. 305	
  306	
ATR-FTIR Spectroscopy  307	
The ATR-FTIR spectra of PVP and Eudragit L-100 fibers are shown in Figure 2. The 308	
spectrum of Eudragit L-100 reveals bands at 3258 cm-1 (-OH), at 2997 cm-1 (-OCH3), 309	
2952 cm-1 (-CH3), and 1731 cm-1(-C=O). The spectrum of PVP reveals bands at 3468 310	
cm-1 (-OH), at 2955 cm-1 (CH2) , at 2876 cm-1 (C-H),  at 1657 cm-1 (C=O),  at 1422 cm-311	
1 (C-H), and  at 1279 cm-1  (C-N) (43). The ATR-FTIR spectra of PVP and Eudragit L-312	
100 fibers indicate the existence of relevant functional groups of PVP and Eudragit L-313	
100. In Figure 2, spectra of pure CBD and CBG are presented, showing two distinct 314	
peaks at 1618 cm-1 and 1577 cm-1, which are assigned to C=C stretch vibration existing 315	
in both CBD and CBG (30). These characteristic peaks of the CBD and CBG are not 316	
detected in the ATR-FTIR spectra of the fibers. Additionally, the characteristic peaks 317	





The thermal analysis of the fibers is presented in Figure 3.  TGA was applied to 321	
investigate the thermal decomposition of fibers. As shown in Figure 3 (A) the thermal 322	
degradation of pure CBD and CBG was completed around 250 °C, close to its boiling 323	
point, whereas PVP and Eudragit L-100 decompose at a higher temperature (450 °C). 324	
Figure 3 (B), (C) presents the recorded TGA thermograms of CBD-loaded fibers, two 325	
significant mass losses can be observed from room temperature to 100 °C and from 326	
200 °C until 300 °C, for drug-loaded fibers. The first mass loss, occurring from 70 °C 327	
to 100 °C is attributed to water loss. The second mass loss of fibers, starting at 200°C 328	
is due to thermal degradation of the polymer matrix and drug.  Similarly, the thermal 329	
stability of CBG-loaded fibers shows a similar pattern (Figure 3 (D), (E)). Specifically, 330	
fibers revealed a weight loss around 100 °C, corresponding to moisture evaporation. 331	
The second event occurring at around 250°C is characteristic of the thermal degradation 332	
of the CBG.  333	
 334	
DSC studies  335	
The DSC thermograms are presented in Figure 4.  In regards to the pure APIs the 336	
characteristic sharp endothermic peaks for both CBD and CBG, located at 68°C and 337	
52°C, respectively, are attributed to the melting point of the two drugs (44). 338	
Additionally, the DSC curves of the drug-loaded fibers exhibited only a wide 339	
endotherm around 100 oC, corresponding to moisture evaporation, with no signs of 340	
APIs’ melting, indicating that both drugs are probably amorphously dispersed within 341	
the prepared fibers matrices. In the case of Eudragit-L100, this hypothesis is verified 342	
by the DSC thermograms of the corresponding physical mixtures (Figure 4 (B), (D)), 343	
where the melting endotherms of the crystalline APIs are clearly depicted. The absence 344	
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of the API endothermic peaks in the case of PVP physical mixtures (Figure 4 (A), (C)) 345	
may be attributed to drugs’ DSC in-situ amorphization. Hence, to verify the 346	
amorphization of both drugs within the tested fiber mats, the physical state of both 347	
components was also evaluated via pXRD analysis.  348	
 349	
pXRD Analysis 350	
Figure 5 shows the pXRD patterns of the analyzed samples. As shown in Figure 5 (Α) 351	
and (Β), pure CBD is crystalline with a characteristic peak at 2θ = 9.8, 17.3, and 21.4°. 352	
Additionally, characteristic peaks of pure CBG are visible in Figure 5 (C) and (D) at 353	
15.2, 20.8, and 23.9°.  Nevertheless, regarding drug-loaded PVP fibers and drug-loaded 354	
Eudragit-L100 fibers, no signs of the peaks were observed justifying the amorphous 355	
state of the drugs encapsulated into the fibers. 356	
 357	
In vitro Release Studies 358	
The in vitro release profile of all the formulations is presented in Figures 6 and 7. PVP 359	
fibers dissolve within 1 h in both SGF and SIF media, whereas Eudragit-L100 fibers 360	
dissolve only in SIF within 2 h. In detail, Figure 6 (A) and 6 (B) depicts the release of 361	
CBD from the PVP fibers in SGF and SIF respectively. Complete dissolution of the 362	
fibers in the SGF medium, within the first 20 to 30 min, results in a 100% release of 363	
CBD, while 2PVP release the drug within 40 min. 1PVP and 2PVP release the drug 364	
within 30 min while 3PVP reaches the 100% release within 40 min. In regards, to drug 365	
release kinetics, the release profile of 1PVP and 3PVP in SGF medium and 1PVP and 366	
2PVP in SIF medium follow the Korsmeyer-Peppas model (R2 = 0.9673 and 0.9916, 367	
respectively; n < 0.5) whereas the release data from 2PVP in SGF medium and 3PVP 368	
in SIF medium follow a first-order model (R2= 0.9947, 0.9776, respectively).  369	
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Figure 6 (C) depicts the release behavior of CBD from the Eudragit fibers. As evident, 370	
CBD release is up to 10% in SGF and as the fibers dissolve in SIF, CBD is completely 371	
released. Release kinetics showed that 7EUDR, 8EUDR, and 9EUDR fibers in the SIF 372	
medium follow the Peppas-Sahlin model (R2 = 0.9674, 0.9272, 0.9674, respectively; m 373	
< 0.5). 374	
Figure 7 presents the release profile of CBG. All formulations have a rapid release 375	
within 30 min, while 6PVP releases the drug in a more controlled way. CBG was 376	
released from PVP fibers in SIF (Figure 7 (B)), within 20 min. The Korsmeyer-Peppas 377	
model was fitted to 4PVP and 5PVP fibers (R2 = 0.9874, 0.9272, respectively, n < 0.5), 378	
and the Peppas-Sahlin model was fitted to 6PVP formulation (R2 = 0.9593, m < 0.5). 379	
All the release data from SIF were fitted to the first-order model (R2 = 0.9654 - 0.9766). 380	
Eudragit fibers release up to 12% of CBG in SGF and complete dissolution of the fibers 381	
in SIF release 100% of the API within 2h. The release data from SIF were fitted to the 382	
first-order model (R2 = 0.9123 - 0.9772).  383	
  384	
Disintegration Test 385	
The disintegration test and wettability studies were carried out by placing 2 cm diameter 386	
circular samples of the fibers in SGF and SIF, recording the whole process using a 387	
digital camera. The results were presented in Figure 8. Specifically, a complete 388	
disintegration of the PVP fibrous structure was occurred in less than 20 sec as evident 389	
from Figure 8 (A) & (B). On the contrary Eudragit L-100 fibers showed the expected 390	
resistance to dissolution in acidic medium (SGF), whereas they appeared to lose their 391	
structure in a moderate rate at neutral pH medium (SIF), resulting in a slow 392	
disintegration of the fibers (Figure 8 (C), (D)). 393	




To evaluate the hydration capacity of drug-loaded Eudragit-L100 fibers, swelling 396	
studies were performed (Figure 9). The water uptake of Eudragit-L100 fibers in SIF 397	
was almost constant for 30 min; then, the samples started to gradually dissolve with an 398	
increasing rate.  399	
 400	
Discussion 401	
The objective of this study was to investigate the incorporation of cannabinoids into a 402	
polymer matrix via the electrospinning process. CBD and CBG loaded fibers were 403	
successfully formed by electrospinning technique utilizing PVP and Eudragit L-100 as 404	
model matrix carriers.  405	
The SEM images of the produced fibers showed that the prepared solutions resulted in 406	
uniform and smooth fibers with a satisfying average diameter. The morphology of the 407	
fibers and the absence of beaded fibers, with non-uniform regions is consistent with 408	
previous reported studies where electrospun fibers comprised of  PVP and Eudragit L-409	
100 (35,37). The formation of ribbon-like shape fibers containing Eudragit L-100 fibers 410	
has been previously reported for fibers with diameters in the range of 1-2 µm (45).  411	
 The amount of the cannabinoids within the electrospun fibers, was quantified by HPLC 412	
analysis. The results are presented in terms of the percentage of loading capacity and 413	
encapsulation efficiency of CBD, CBG (Table 3). The high encapsulation efficiency 414	
(>90%) is attributed to the  electrospinning process, due to rapid solvent evaporation 415	
and fast fiber formation (32).  416	
The fabricated fibers along with the pristine materials and their physical mixtures, were 417	
analyzed by ATR-FTIR, to investigate the presence of any possible change of the 418	
chemical structure of the system during the electrospinning process. The absence of the 419	
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characteristic peaks of the two cannabinoids from both the fibers and the physical 420	
mixtures, is a strong indication that the amount of API within the samples is below the 421	
detection limit of the instrument, and thus the deduction of any conclusion regarding 422	
the amorphization of the API is not safe.   423	
To further investigate the thermophysical properties of the electrospun fibers, TGA 424	
analysis was performed. The thermograms are indicative of the hydroscopic nature of 425	
both polymers, as there is a mass loss that is attributed to moisture evaporation from 426	
the fibers. On the other hand, the mass loss that is observed for all the samples due to 427	
APIs’ phase change close to their respective boiling points, is an indication that there 428	
the thermal properties of the cannabinoids (Tm) have not been altered.  429	
The thermophysical properties of the system were further studied by means of  DSC 430	
analysis. Τhe DSC thermograms of the pure APIs, illustrated the characteristic 431	
endothermic peaks of CBD and CBG at 62°C and 58°C, respectively, attributed to their 432	
melting point (30,31,44). The absence of these peaks in the drug-loaded fibers implies 433	
that the APIs could be in amorphous state (34).  434	
 To verify the amorphous state of the selected cannabinoids, the pXRD studies were 435	
performed to the formatted fibers.  pXRD patterns of pure drugs showed characteristic 436	
peaks of their crystalline structure (29). On the other hand, the diffractograms of PVP 437	
and Eudragit L-100 fibers reveal broad halos typical for amorphous materials (46). The 438	
absence of the characteristic peaks of the CBD and CBG from the diffractograms is 439	
attributed to the amorphous state of the two substances within the electrospun fibers.  440	
The release profiles of the two model cannabinoids from the prepared electrospun fibers 441	
were studied in vitro. The studies indicated a burst release of CBD and CBG from PVP 442	
fibers in SGF and SIF media, whereas both APIs were released from Eudragit L-100 443	
fibers in a pH-controlled manner, exhibiting negligible release in lower pH values (SGF 444	
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medium) and a burst release in the simulated intestinal environment (SIF medium). 445	
These observations are consistent with similar systems previously described in the 446	
literature (35,46,47), as PVP fibers are readily dissolvable in aqueous media (both SGF 447	
and SIF), while Eudragit L-100 fibers are not dissolvable in acidic environment. The 448	
release data obtained for the samples 1PVP and 3PVP in SGF and 1PVP and 2PVP in 449	
SIF were best fitted to the Korsmeyer-Peppas kinetic model, and based on the ‘n’ values, 450	
it was concluded that the release is governed by Fickian diffusion (n < 0.5) (48–50). On 451	
the other hand, CBD is released from 2PVP in SGF and 3PVP in SIF medium following 452	
the first-order model, indicating that CBD is released in a constant rate between the 453	
amount of the drug remaining in the polymer matrix and the released drug (51). In either 454	
case, the release of CBD from PVP fibers is mainly affected by the fast dissolution rate 455	
of the polymeric fiber, due to the highly hydrophilic nature of PVP (52).   456	
The release profiles of CBD from Eudragit L-100 fibers were studied in SIF medium, 457	
as the fibers were not dissolved in acidic environment. The release data obtained for 458	
the samples 7EUDR, 8EUDR, and 9EUDR in SIF were fitted to the Peppas-Sahlin 459	
model (R2 = 0.9674, 0.9272, 0.9674, respectively; m < 0.5), indicating that the release 460	
of the API is owed to diffusion and relaxation of the polymeric chains (53), attributed 461	
to the time-dependent swelling of the polymer, in SIF medium (35,46).  462	
The in vitro release studies of CBG-containing electrosun fibers, were in close 463	
agreement with those obtained for CBD. All formulations exhibited a rapid release 464	
within 30 min, with the exception of 6PVP where drug release was slower. The 465	
Korsmeyer-Peppas model was fitted to samples 4PVP and 5PVP (R2 = 0.9874, 0.9272, 466	
respectively, n < 0.5), and the Peppas-Sahlin model was best-fitted to sample 6PVP (R2 467	
= 0.9593, m < 0.5). All the release data obtained for SIF medium, were fitted to the 468	
first-order model (R2 = 0.9654 - 0.9766). In a similar way to CBD release from drug-469	
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loaded PVP fibers, the phenomenon is governed mainly by the fast dissolution of the 470	
polymer (as it is described by the Korsmeyer-Peppas model), with the exception of the 471	
sample 6PVP, where the swelling of the polymer seems to play a minor role, indicating 472	
the presence of drug-polymer interaction of a low extent.  473	
Eudragit fibers released up to 12% of CBG in SGF and complete dissolution of the 474	
fibers in SIF release 100% of the API within 2h. The release data from SIF were fitted 475	
to the first-order model (R2 = 0.9123 - 0.9772), indicating the fast dissolution rate of 476	
the polymer in SIF medium.  477	
To visualize the fast dissolution rates of both polymers in the studied media, the in vitro 478	
disintegration test was applied to the electrospun fibers (42). Drug-loaded PVP fibers 479	
were completely wetted and disintegrated in both simulated fluids (SGF, SIF) losing 480	
their original shape within 20 s, as illustrated in Figure 8 (A) and (B). This rapid 481	
disintegration of drug-loaded PVP fibers in both simulated fluids might be attributed to 482	
the highly porous structure of the produced fibers during the electrospinning process 483	
(55). The porosity of fibers is related to their ability to absorb large quantities of water 484	
causing their disintegration in a few seconds. Hence, it can be deduced that the rapid 485	
disintegration of fiber structure allowed at the same time the fast release of the drug 486	
from the polymer matrix (47).  487	
The disintegration time of drug-loaded Eudragit L-100 fiber mats could not be precisely 488	
determined due to the controlled dissolution of the polymer matrix. Hence, the results 489	
obtained from the time-lapsed videos (Figure 8 (C), (D)) show a wetting behavior of 490	
the fiber mats in SIF until 300 sec with a time-dependent erosion in the polymer matrix. 491	
On the contrary, drug-loaded Eudragit fibers are insoluble in acidic pH (SGF pH 1.2)	492	
as shown in Figure 8 (C), (D).  To this context, the rate and the extent of Eudragit L-493	
100 fibers hydration were investigated at an acidic medium (SGF) and a neutral pH 494	
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medium (SIF), to monitor and mimic the transition from gastric to intestinal 495	
environment (30). The maximum water uptake was achieved within the first 20 min in 496	
both simulated fluids with the the polymer matrix preserving its structure in the acidic 497	
medium, whereas a complete disintegration of the fiber structure was observed in SIF 498	
medium at the timescale of 2h in pH = 6.8.  499	
 500	
Conclusions 501	
To our best knowledge this the first report where electrospinning process was 502	
successfully applied to produce submicron fibers containing the model cannabinoids 503	
CBD and CBG accordingly. The incorporation of the two poorly water-soluble APIs in 504	
two different model excipients (PVP and Eudragit L-100) has led to the increase of 505	
CBD’s and CBG’s solubility, rendering this manufacturing approach suitable for the 506	
preparation of water-soluble formulations for per os administration of cannabinoids.   507	
 508	
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CBD 2PVP 1 
3PVP 1.5 
4PVP 0.5 







CBD 8 EUDR  1 
9 EUDR  1.5 
10EUDR 0.5 
CBG 11EUDR 1 
12EUDR 1.5 
*Final polymer concentration in ethanol 




Table 2. Apparent viscosity and conductivity values of the spinning solutions. 688	
Electrospinning solutions Viscosity (Pa·s) Conductivity (µS/cm) 
PVP 0.536 ±0.045 67.5 ±0.4 







Table 3. Loading capacity (%) and Encapsulation efficiency (%) of the formulations. 695	
Sample Loading Capacity (%) Encapsulation efficiency (%) 
1PVP 0.47 93.90 
2PVP 0.99 99.00 
3PVP 1.48 98.10 
4PVP 0.49 98.56 
5PVP 0.97 97.10 
6PVP 1.46 97.13 
30	
	
7EUDR 0.45 90.50 
8EUDR 0.95 95.45 
9EUDR 1.48 98.50 
10EUDR 0.49 98.88 
11EUDR 0.94 93.65 






















Figure 1. SEM images and average diameter distribution histograms of a. CBD loaded 717	
PVP fibers (A) PVP, (B) 1PVP, (C) 2PVP, (D) 3PVP, b. CBD loaded Eudragit L-100 718	
fibers I Eudragit L-100, (F) 7EUDR, (G) 8EUDR, (H)9EUDR, c. CBG loaded PVP 719	
fiber mats (I)PVP, (J)4PVP, (K)5PVP, (L)6PVP, d. CBG loaded Eudragit L-100 fibers 720	




Figure 2. ATR-FTIR spectra of (A) as-spun PVP/CBD fibers and Physical mixtures, 723	
(B)  as-spun Eudragit L-100/CBD fibers and Physical mixtures, (C) as-spun PVP/CBG 724	
fibers and Physical mixtures, (D) as-spun Eudragit L-100/CBG fibers and Physical 725	
mixtures. 726	
 727	
Figure 3. TGA results of nanofibers: (A) Raw material, (B) as spun PVP/CBD fibers, 728	
(C) as spun Eudragit L-100/CBD fibers, (D) as spun PVP/CBG fibers, (E) as spun 729	
Eudragit L-100/CBG fibers. 730	
 731	
Figure 4. DSC thermograms of nanofibers: (A) PVP/CBD fibers and Physical mixtures, 732	
(B) Eudragit L-100/CBD fibers and Physical mixtures, (C) PVP/CBG fibers and 733	
Physical mixtures, (D) Eudragit L-100/CBG fibers and physical mixtures. 734	
 735	
Figure 5. pXRD pattern of (A) PVP/CBD fibers; (B) Eudragit L-100/CBD fibers, (C) 736	
PVP/CBG fibers, (D) Eudragit L-100/CBG fibers. 737	
 738	
Figure 6. Release profile of CBD from PVP fibers in (A) SGF and (B) SIF and from 739	
Eudragit fibers (C) in SGF and SIF.  740	
Figure 7. Release profile of CBG from PVP fibers in (A) SGF and (B) SIF and from 741	
Eudragit fibers (C) in SGF and SIF.  742	
 743	
Figure 8. Disintegration test of fiber in Simulated fluids: (A) 3PVP in SGF and SIF, 744	




Figure 9.  Swelling plot of drug-loaded Eudragit L-100 fibers: (A) in SGF, (B) in SIF 747	
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